Eravacycline is a synthetic halogenatedtetracycline class antibiotic in development by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections and complicated urinary tract infections were recently completed with mixed results. Eravacycline has been granted fast track designation by the FDA.
Medical uses
Eravacycline has shown broad spectrum of activity against a variety of Gram-positive and Gram-negative bacteria, including multi-drug resistant strains, such as methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae. It is currently being formulated as for intravenous and oral administration.
Spectrum of activity
Gram-positive organisms
Staphylococcus aureus
Streptococcus pneumoniae
Enterococcus faecalis
Enterococcus faecium
Gram-negative organisms
Acinetobacter baumannii
Stenotrophomonas maltophilia
Haemophilus influenzae
Moraxella catarrhalis
Neisseria gonorrhoeae
Enterobacteriaceae
* Escherichia coli
* Klebsiella pneumoniae
* Klebsiella oxytoca
* Enterobacter species
* Citrobacter species
* Proteus mirabilis
* Serratia marcescens
Similar to other tetracycline derivatives, eravacylcine is poorly active against Pseudomonas aeruginosa with a MIC90= 16 mcg/mL . Eravacycline maintains in-vitro activity against Enterobacteriaceae carrying the mcr-1 gene responsible for polymyxin b/colistin resistance.
Clinical trials
Current and past clinical trial information: https://clinicaltrials.gov/ct2/results?cond=&term=eravacycline&cntry1=&state1=&recrs=
Phase 3 trials
Complicated Intra-abdominal infections (IGNITE 1)
The IGNITE 1 trial compared twice-daily IV eravacycline to once-daily ertapenem for the treatment of cIAI. A total of 541 patients were included and eravacycline demonstrated noninferiority to ertapenem. An additional pivotal phase 3 study is planned for late 2016 with initial results likely available in the fourth quarter of 2017.
IGNITE 4 assessed twice-daily intravenous eravacycline compared to those receiving meropenem. The study enrolled 500 adult patients with the primary endpoint being clinical response at the test-of-cure visit which is 25–31 days after initial dosing. Primary efficiency analysis was conducted using a 12.5% non-inferiority margin in the microbiological intent-to-treat population. On July 25, 2017 Tetraphase pharmaceuticals released top line data via press showing clinical cure rates in the micro-ITT population to be 90.8% and 91.2% for eravacycline and meropenem, respectively. Primary analysis was conducted using a 12.5% non-inferiority margin of the modified intent-to-treat and clinically evaluable patient populations. Clinical cure rates in the MITT population were 92.4% and 91.6% for eravacycline and meropenem, respectively. Clinical cure rates in the CE population were 96.9% and 96.1% for eravacycline and meropenem, respectively. Eravacycline met the primary efficacy endpoints according to the FDA and EMA guidelines. The secondary analyses were consistent with, and supportive of, the primary outcome according to Tetraphase. There were no treatment-related serious adverse events in the trial. Treatment-emergent adverse event rates were similar in both treatment groups with the most commonly reported drug-related adverse events for eravacycline were infusion site reactions, nausea and vomiting, each occurring at a rate of less than 5%. The most common Gram-negative pathogens in the study included Escherichia coli, Klebsiella pneumoniae, Pseudomonas and Bacteroides. Full data from IGNITE4 will become available as the company prepares to submit its New Drug Application in the first quarter of 2018 for Eravacycline treatment of Complicated Intra-abdominal Infections.
The IGNITE 2 trial compared 7 days of IV eravacycline to IV levofloxacin with the option to convert patients in either group to oral therapy after 3 days for cUTI. Overall, eravacyline was inferior to levofloxacin in response rate ; however it was noted that patients who completed therapy with the IV formulation had higher response rates, suggesting formulation issues with the oral option. Due to the performance of the IV formulation, an additional phase 3 trial is planned to support a supplemental NDA for the cUTI indication.
IGNITE3 is currently ongoing starting January 2017 with expected completion December 2018. This study is evaluating IV eravacycline compared to ertapenem for the treatment of cUTI. IGNITE3 is currently enrolling approximately 1,000 patients who will be randomized 1:1 to receive intravenous eravacycline or ertapenem for a minimum of 5 days, and will then be eligible for transition to oral levofloxacin. The primary endpoints are Proportion of Participants in the microbiological Intent-to-treat Population demonstrating Clinical Cure and Microbiologic Success at the End of Intravenous Visit & Proportion of Participants in the micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure Visit . With secondary endpoints testing Proportion of Participants in the microbiological Modified Intent-To-Treat Population and the Microbiologically Evaluable Population Demonstrating Microbiologic Success at the TOC Visit
